Perrigo sharpens focus on consumer healthcare

6 March 2017 - Deborah Wilkes

Archived

Perrigo is sharpening its focus on consumer healthcare following pressure from an activist investor. The troubled company has agreed to divest its rights to the royalty stream from Tysabri (natalizumab) – the multiple sclerosis treatment marketed by Biogen – and is reviewing strategic alternatives for its Active Pharmaceutical Ingredients (API) business.

Annual Subscription Holder?

Sign in to continue reading.
 

Sign In

Back to Industry News

Share this page: